ArticleCell death and differentiation2026
Inhibition of tPA-NMDAR interaction prevents neurovascular and functional deficits induced by organophosphorus nerve agents.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Organophosphorus compounds (OP), including pesticides and nerve agents such as sarin, soman and Novichok, irreversibly inhibit cholinesterases (ChE), resulting in excessive cholinergic signaling, excitotoxicity, and neuroinflammation. Although current countermeasures provide partial protection, OP exposure remains associated with central nervous system (CNS) damage, including blood-brain barrier (BBB) disruption and cognitive impairments. In this study, we identify a critical role for tissue-type plasminogen activator (tPA)-a serine protease that modulates neuronal and endothelial N-methyl-D- aspartate receptor (NMDAR) signaling-in mediating OP-induced brain injury. Using a murine model exposed to soman or the nerve agent surrogate 4-nitrophenyl isopropylmethylphosphonate (NIMP), we show that OP exposure elevates circulating tPA levels, exacerbating neuroinflammation, BBB leakage, and neurovascular coupling impairment. Notably, blockade of the tPA-NMDAR interaction using Glunomab, a monoclonal antibody, prevents these effects. Our findings identify tPA-NMDAR signaling as a key mediator of OP-induced CNS damage and a promising therapeutic target.
Identifiers
41917181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.